Biosensor‐Enabled Multiplexed On‐Site Therapeutic Drug Monitoring of Antibiotics. Issue 2 (21st September 2021)

• Record Type: Journal Article
• Authors: Ates, H. Ceren; Mohsenin, Hasti; Wenzel, Christin; Glatz, Regina T.; Wagner, Hanna J.; Bruch, Richard; Hoefflin, Nico; Spassov, Sashko; Streicher, Lea; Lozano‐Zahonero, Sara; Flamm, Bernd; Trittler, Rainer; Hug, Martin J.; Köhn, Maja; Schmidt, Johannes; Schumann, Stefan; Urban, Gerald A.; Weber, Wilfried; Dincer, Can
• Is Part Of: Advanced materials. Volume 34:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-09-21
• Subjects: ß‐lactam antibiotics -- exhaled breath condensate -- multiplexing -- noninvasive diagnostics -- point‐of‐care testing; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adma.202104555
• Languages: English
• ISSNs: 0935-9648

Abstract

Abstract: Personalized antibiotherapy ensures that the antibiotic concentration remains in the optimal therapeutic window to maximize efficacy, minimize side effects, and avoid the emergence of drug resistance due to insufficient dosing. However, such individualized schemes need frequent sampling to tailor the blood antibiotic concentrations. To optimally integrate therapeutic drug monitoring (TDM) into the clinical workflow, antibiotic levels can either be measured in blood using point‐of‐care testing (POCT), or can rely on noninvasive sampling. Here, a versatile biosensor with an antibody‐free assay for on‐site TDM is presented. The platform is evaluated with an animal study, where antibiotic concentrations are quantified in different matrices including whole blood, plasma, urine, saliva, and exhaled breath condensate (EBC). The clearance and the temporal evaluation of antibiotic levels in EBC and plasma are demonstrated. Influence of matrix effects on measured drug concentrations is determined by comparing the plasma levels with those in noninvasive samples. The system's potential for blood‐based POCT is further illustrated by tracking ß‑lactam concentrations in untreated blood samples. Finally, multiplexing capabilities are explored successfully for multianalyte/sample analysis. By enabling a rapid, low‐cost, sample‐independent, and multiplexed on‐site TDM, this system can shift the paradigm of "one‑size‐fits‐all" strategy. Abstract : The first electrochemical biosensor, with a synthetic‐biology‐enabled antibody‐free assay, for temporal monitoring of piperacillin/tazobactam in exhaled breath condensate, along with a correlation study exploring the link between monitored drug levels, is presented. The validation of the findings with gold‐standard measurements demonstrates the suitability of the system as a low‐cost, rapid, and sample‐independent tool for multiplexed on‐site therapeutic drug monitoring.